Fortis Oncology was formed in 2013 to commercialize nanomaterial-containing medical devices and diagnostic products for photothermal ablation of tumors. It acquired intellectual property from Wake Forest University developed over 5 years demonstrating ablation of primary tumors and cancer stem cells in animal studies. Fortis is now seeking investment to bring these nanothermal products to market approval to destroy cancer while sparing healthy tissue, changing cancer treatment. It is working with several leading institutions and is focused on developing advanced MRI contrast agents, medical devices for thermal cancer ablation, and devices using functionalized carbon nanotubes for thermal ablation with anti-cancer drugs.

1. It our strategy to exit the platforms (MRI diagnostic contrast reagents and therapeutic medical devices)
independently to maximize shareholder value. We will exit the MRI contrast reagents business when
mature and generating sufficient cash flow to fund further development of higher-margin therapeutic
device products, in a range of cancer indications.
Fortis Oncology was formed in August,
2013 to commercialize advanced
nanomaterial-containing medical devices
and diagnostic products for the
photothermal ablation of tumors.
Fortis acquired global licensing rights to
intellectual property developed by
leading researchers at Wake Forest
University School of Medicine. Wake
Forest Innovations and Angels led Fortis’
seed round.
Prior to Fortis’ acquisition of the IP, more
than 5 years of preclinical work was
completed, including the demonstration
of proof-of-concept in large animal in vivo
clinical studies. Studies demonstrated
ablation of primary tumor as well as the
destruction of metastatic cancer stem
cells.
Our aim is to bring advanced,
nanothermal products to market approval
that not only destroy cancer, but spare
healthy tissue, in a fraction of the time
required by conventional therapies and in
doing so, change the face of cancer
treatment as we know it forever. Fortis is
now seeking investment for what will be
a sustainable, profitable business.
The company is initiating important re-
search and clinical projects with leading
institutions including:
Wake Forest Medical School
MD Andersen Cancer Center
Vanderbilt University
University of Pittsburgh Medical Center
Memorial Sloan-Kettering
Mount Sinai Medical Center
University of Pennsylvania
National Cancer Institute
Paul Rohricht MS MBA, Founder & CEO
John Stewart MD, Founder & CMO
Nicole Levi-Polychenko PhD, Founder &
CSO
Paul Rohricht MS MBA, CEO
+1 (704)237-0213
paulrohricht@fortisoncology.com
www.fortisoncology.com©2013 Fortis Oncology. All rights reserved
This document may contain forward-looking statements.
Fortis Oncology is currently focused on
three specific product development
initiatives to diagnose and treat kidney,
prostate, soft-tissue neoplasms, bone
neoplasms, and interperitoneal
cancers. Products include:
 Advanced MRI contrast reagents;
 Medical devices for the thermal
ablation of cancers;
 Medical devices for the thermal
ablation of cancers in which
MWCNTs are functionalized with
tumorigenic APIs.
http://www.pnas.org/content/
Fortis Oncology was awarded US patents 8,252,772
(“Hyperthermic Technologies and Uses Thereof”) and US
8,501,233 (“Compositions and Methods for Treating Can-
cer”). In addition, we have an extensive IP estate in vari-
ous stages of prosecution in leading worldwide markets
that also include thermal ablation with drug delivery by
MWCNT’s.